Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast Cancer

Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast Cancer

<b>Background:</b> Ontario publicly funds reference trastuzumab (Herceptin) and four biosimilar trastuzumab products for adjuvant treatment of HER2+ breast cancer. We assessed the real-world safety and effectiveness of biosimilar trastuzumab compared to Herceptin for adjuvant treatment o...

Full description

Bibliographic Details
Main Authors: Caroline Muñoz, Xiaochen Tai, Jessica Arias, Andrea Eisen, Munaza Chaudhry, Scott Gavura, Kelvin K. W. Chan
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Current Oncology
Subjects:
real-world evidence
real-world data
cohort
biosimilar
originator
oncology
Online Access:https://www.mdpi.com/1718-7729/31/3/124

Internet

https://www.mdpi.com/1718-7729/31/3/124

Similar Items